1[1]NIH Consensus Development Panel on Osteoporosis Prevention. Diagnosis and Therapy. JAMA 2001,285:785-795.
2[2]Weinstein RS. True strength. J Bone Miner Res 2000,15:621-625.
3[3]Chesnut Ⅲ CH, Rosen CJ for the Bone Quality Discussion Group. Reconsidering the effects of antiresorptive therapies in reducing osteoporotic fracture. J Bone Miner Res 2001,16:2163-2172.
4[4]Marcus R, Wong M, Heath Ⅲ H, et al. Antiresorptive treatment of posrmenopausal osteoporosis: comparison of study designs and outcomes in large clinical trials with fracture as an endpoint. Endocrine Rev 2002,23:16-37.
5[5]Orimo H, Hayashi Y, Fukunaga M, et al. Diagnostic criteria for primary osteoporosis: year 2000 revision. J Bone Miner Metab 2001,19:331-337.
6[6]Cummings SR, Karpf DB, Harris F, et al. Improvement of spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med 2002,112: 282-289.
7[7]Heaney RP. Is the paradigm shifting? Bone 2003,33:457-465.
8[8]Garnero P, Hausherr E, Chapuy MC, et al. Markers of bone resorption predict hip fracture in elderly women; EPIDOS prospective study. J Bone Mineral Res 1996,11:1531-1538.
9[9]Garnero P, Sornay-Rendu E, Claustrar B, et al. Biochemical markers of bone turnover, endogenous hormones and the risk of fracture in postmenpausal women: the OFELY study. J Bone Miner Res 2000, 15: 1526-1536.
10[10]Ross PD, Kress BC, Parson RE, et al. Serum bone alkaline phosphatase and calcaneus bone density predict fractures; a prospective study. Osteoporos Int 2000,11:76-82.
